Caplin Point Laboratories Ltd. — Investor Relations & Filings
Caplin Point Laboratories Ltd. is a pharmaceutical organization focused on the development, manufacturing, and marketing of finished dosage forms. Its extensive product portfolio encompasses tablets, capsules, injections, liquid orals, and softgel capsules across diverse therapeutic categories. The company utilizes a vertically integrated business model, overseeing the complete value chain from research and development to final distribution. Caplin Point maintains a significant market presence in Latin America and Francophone Africa, supported by a specialized end-to-end logistics and supply chain network. Furthermore, through its subsidiary Caplin Steriles, the company has established a footprint in regulated markets, specializing in sterile injectables and ophthalmic products. Its manufacturing infrastructure is designed to meet global regulatory requirements, including certifications from the US FDA and EU GMP.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-07 | English | |
| Press Release | 2026-05-05 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | |
| Trading Window | 2026-03-27 | English | |
| Press Release | 2026-03-13 | English | |
| Cessation | 2026-03-03 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42853900 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-05-07 | English | ||
| 42193426 | Press Release | 2026-05-05 | English | ||
| 42209107 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | ||
| 42213262 | Trading Window | 2026-03-27 | English | ||
| 42199015 | Press Release | 2026-03-13 | English | ||
| 42175465 | Cessation | 2026-03-03 | English | ||
| 42190574 | Press Release | 2026-02-28 | English | ||
| 42185175 | Press Release | 2026-02-24 | English | ||
| 42197934 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-11 | English | ||
| 42162579 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-05 | English | ||
| 42180729 | Investor Presentation | 2026-02-05 | English | ||
| 42183832 | Outcome of Board Meeting | 2026-02-05 | English | ||
| 42220110 | Change in Director(s) | 2026-02-03 | English | ||
| 42220381 | Shareholders meeting | 2026-02-03 | English | ||
| 42173993 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-01-29 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BriaCell Therapeutics Corp.
Developing targeted cellular immunotherapies using whole-ce…
|
BCTX | CA | Manufacturing |
|
BridgeBio Oncology Therapeutics, Inc.
Clinical-stage biopharma developing inhibitors for genetica…
|
BBOT | US | Manufacturing |
|
BridgeBio Pharma, Inc.
Develops transformative medicines for genetic diseases and …
|
BBIO | US | Manufacturing |
|
Brightgene Bio-Medical Technology Co., Ltd.
Research-driven developer of complex APIs, high-end generic…
|
688166 | CN | Manufacturing |
|
BRIGHT MINDS BIOSCIENCES INC.
Develops selective serotonin agonists for neurological and …
|
DRUG | US | Manufacturing |
|
BrightPath Biotherapeutics Co., Ltd.
A clinical-stage biopharma company developing cancer immuno…
|
4594 | JP | Manufacturing |
|
Brii Biosciences Limited
Developing first-in-class therapies targeting infectious an…
|
2137 | KY | Manufacturing |
|
BRISTOL MYERS SQUIBB CO
A global biopharmaceutical company that discovers, develops…
|
BMY | US | Manufacturing |
|
BROOKS LABORATORIES LIMITED
Pharmaceutical manufacturer specializing in CRAMS and diver…
|
BROOKS | IN | Manufacturing |
|
BUKWANG PHARMACEUTICAL IND CO.,LTD
An R&D-focused company developing drugs for CNS disorders a…
|
003000 | KR | Manufacturing |
Caplin Point Laboratories Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61439/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61439 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61439 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61439 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61439}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Caplin Point Laboratories Ltd. (id: 61439)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.